These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7494622)

  • 1. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis.
    Friedman JA; Dwyer JT
    Nutr Rev; 1995 Jul; 53(7):197-201. PubMed ID: 7494622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
    Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
    Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia as a cause of vascular occlusion in end-stage-renal disease.
    Tamura T; Bergman SM; Morgan SL
    Int J Artif Organs; 1998 Feb; 21(2):72-4. PubMed ID: 9569127
    [No Abstract]   [Full Text] [Related]  

  • 5. Homocysteine targeting of plasma proteins in hemodialysis patients.
    Jacobsen DW
    Kidney Int; 2006 Mar; 69(5):787-9. PubMed ID: 16518339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis.
    Tamadon MR; Jamshidi L; Soliemani A; Ghorbani R; Malek F; Malek M
    Iran J Kidney Dis; 2011 Mar; 5(2):93-6. PubMed ID: 21368386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M; Serbelloni P; Milani S; Ferrario G
    Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid.
    Chiarello PG; Vannucchi MT; Moysés Neto M; Vannucchi H
    Int J Vitam Nutr Res; 2003 Nov; 73(6):431-8. PubMed ID: 14743547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation].
    Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L
    Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online.
    Melero-Rubio E; Párraga-Díaz M; Gómez-Sánchez MP; Pellicer-Villaescusa S; Merchán-Mayado E
    J Ren Care; 2009 Dec; 35(4):201-4. PubMed ID: 19909413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine as a cardiovascular risk factor.
    Biasioli S; Schiavon R
    Blood Purif; 2000; 18(3):177-82. PubMed ID: 10859420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperhomocysteinemia in children on dialysis by folic acid.
    Schröder CH; de Boer AW; Giesen AM; Monnens LA; Blom H
    Pediatr Nephrol; 1999 Sep; 13(7):583-5. PubMed ID: 10460506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia and cardiovascular risks in hemodialysis patients.
    Sagheb MM; Ostovan MA; Sohrabi Z; Atabati E; Raisjalai GA; Roozbeh J
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):863-6. PubMed ID: 20814121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients.
    Morimoto K; Haneda T; Okamoto K; Ishida H; Kikuchi K
    Nephron; 2002 Jan; 90(1):43-50. PubMed ID: 11744804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.
    Taes YE; Delanghe JR; De Bacquer D; Langlois M; Stevens L; Geerolf I; Lameire NH; De Vriese AS
    Kidney Int; 2004 Dec; 66(6):2422-8. PubMed ID: 15569335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
    Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
    J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
    Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
    Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.